Research/art/teacher profile of a person
Name and surname:
PharmDr. Eva Malíková, PhD.
Document type:
Research/art/teacher profile of a person
The name of the university:
Comenius University Bratislava
The seat of the university:
Šafárikovo námestie 6, 818 06 Bratislava

I. - Basic information

I.1 - Surname
Malíková
I.2 - Name
Eva
I.3 - Degrees
Mgr., PharmDr., PhD.
I.4 - Year of birth
1987
I.5 - Name of the workplace
Faculty of Pharmacy, Comenius University, Bratislava
I.6 - Address of the workplace
Faculty of Pharmacy, Comenius University, Odbojárov 10 832 32 Bratislava
I.7 - Position
post-doc researcher, teacher
I.8 - E-mail address
malikova15@uniba.sk
I.9 - Hyperlink to the entry of a person in the Register of university staff
https://www.portalvs.sk/regzam/detail/26286
I.10 - Name of the study field in which a person works at the university
Pharmacology
I.11 - ORCID iD
0000-0002-8229-3518

II. - Higher education and further qualification growth

II.1 - First degree of higher education
II.2 - Second degree of higher education
II.a - Name of the university or institution
Faculty of Pharmacy, Comenius University
II.b - Year
2012
II.c - Study field and programme
Pharmacy
II.3 - Third degree of higher education
II.a - Name of the university or institution
Faculty of Pharmacy, Comenius University
II.b - Year
2017
II.c - Study field and programme
Pharmacology
II.4 - Associate professor
II.5 - Professor
II.6 - Doctor of Science (DrSc.)

III. - Current and previous employment

III.a - Occupation-position III.b - Institution III.c - Duration
post-doc researcher, teacher Faculty of Pharmacy, Comenius University 2016-
preclinical and clinical assessor State institute for drug control 2016-

IV. - Development of pedagogical, professional, language, digital and other skills

V. - Overview of activities within the teaching career at the university

V.1 - Overview of the profile courses taught in the current academic year according to study programmes
V.2 - Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year
V.3 - Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year
V.4 - Overview of supervised final theses
V.4.1 - Number of currently supervised theses
V.4.b - Diploma (second degree)
5
V.4.2 - Number of defended theses
V.4.b - Diploma (second degree)
5
V.5 - Overview of other courses taught in the current academic year according to study programmes
V.5.a - Name of the course V.5.b - Study programme V.5.c - Degree V.5.d - Field of study
Pathology of rare diseases Pharmacy
Pharmacology of drugs for rare diseases Pharmacy

VI. - Overview of the research/artistic/other outputs

VI.1 - Overview of the research/artistic/other outputs and the corresponding citations
VI.1.1 - Number of the research/artistic/other outputs
VI.1.a - Overall
55
VI.1.b - Over the last six years
55
VI.1.2 - Number of the research/artistic/other outputs registered in the Web of Science or Scopus databases
VI.1.a - Overall
16
VI.1.b - Over the last six years
16
VI.1.3 - Number of citations corresponding to the research/artistic/other outputs
VI.1.a - Overall
23
VI.1.b - Over the last six years
23
VI.1.4 - Number of citations registered in the Web of Science or Scopus databases
VI.1.a - Overall
23
VI.1.b - Over the last six years
23
VI.1.5 - Number of invited lectures at the international, national level
VI.1.a - Overall
0
VI.1.b - Over the last six years
0
VI.2 - The most significant research/artistic/other outputs
1
Effects of inorganic nitrate in a rat model of monocrotaline-induced pulmonary arterial hypertension

Malikova, E., Carlström, M., Kmecova, Z., ...Klimas, J., Henrohn, D.

Basic and Clinical Pharmacology and Toxicology, 2020, 126(2), pp. 99–109

2

Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseases.Sheean ME, Malikova E, Duarte D, Capovilla G, Fregonese L, Hofer MP, Magrelli A, Mariz S, Mendez-Hermida F, Nistico R, Leest T, Sipsas NV, Tsigkos S, Vitezic D, Larsson K, Sepodes B, Stoyanova-Beninska V.

Drug Discov Today. 2020 Feb;25(2):274-291. doi: 10.1016/j.drudis.2019.10.015. Epub 2019 Nov 5.

3

Local and systemic renin-angiotensin system participates in cardiopulmonary-renal interactions in monocrotaline-induced pulmonary hypertension in the rat.

Malikova E, Galkova K, Vavrinec P, Vavrincova-Yaghi D, Kmecova Z, Krenek P, Klimas J.

Mol Cell Biochem. 2016 Jul;418(1-2):147-57. doi: 10.1007/s11010-016-2740-z. Epub 2016 Jun 25.

4

Pioglitazone restores phosphorylation of downregulated caveolin-1 in right ventricle of monocrotaline-induced pulmonary hypertension.

Malikova E, Kmecova Z, Doka G, Pivackova LB, Balis P, Trubacova S, Velasova E, Krenek P, Klimas J.

Clin Exp Hypertens. 2021 Nov 7:1-12. doi: 10.1080/10641963.2021.1996589. Online ahead of print.

5

Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit-The EU Regulator's Perspective.Sheean ME, Naumann-Winter F, Capovilla G, Kalland ME, Malikova E, Mariz S, Matusevicius D, Nistico R, Schwarzer-Daum B, Tsigkos S, Tzogani K, Larsson K, Magrelli A, Stoyanova-Beninska V.

Front Med (Lausanne). 2021 Aug 27;8:744625. doi: 10.3389/fmed.2021.744625. eCollection 2021.

VI.3 - The most significant research/artistic/other outputs over the last six years
1
Effects of inorganic nitrate in a rat model of monocrotaline-induced pulmonary arterial hypertension

Malikova, E., Carlström, M., Kmecova, Z., ...Klimas, J., Henrohn, D.

Basic and Clinical Pharmacology and Toxicology, 2020, 126(2), pp. 99–109

2

Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseases.Sheean ME, Malikova E, Duarte D, Capovilla G, Fregonese L, Hofer MP, Magrelli A, Mariz S, Mendez-Hermida F, Nistico R, Leest T, Sipsas NV, Tsigkos S, Vitezic D, Larsson K, Sepodes B, Stoyanova-Beninska V.

Drug Discov Today. 2020 Feb;25(2):274-291. doi: 10.1016/j.drudis.2019.10.015. Epub 2019 Nov 5.

3

Local and systemic renin-angiotensin system participates in cardiopulmonary-renal interactions in monocrotaline-induced pulmonary hypertension in the rat.

Malikova E, Galkova K, Vavrinec P, Vavrincova-Yaghi D, Kmecova Z, Krenek P, Klimas J.

Mol Cell Biochem. 2016 Jul;418(1-2):147-57. doi: 10.1007/s11010-016-2740-z. Epub 2016 Jun 25.

4

Pioglitazone restores phosphorylation of downregulated caveolin-1 in right ventricle of monocrotaline-induced pulmonary hypertension.

Malikova E, Kmecova Z, Doka G, Pivackova LB, Balis P, Trubacova S, Velasova E, Krenek P, Klimas J.

Clin Exp Hypertens. 2021 Nov 7:1-12. doi: 10.1080/10641963.2021.1996589. Online ahead of print.

5

Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit-The EU Regulator's Perspective.Sheean ME, Naumann-Winter F, Capovilla G, Kalland ME, Malikova E, Mariz S, Matusevicius D, Nistico R, Schwarzer-Daum B, Tsigkos S, Tzogani K, Larsson K, Magrelli A, Stoyanova-Beninska V.

Front Med (Lausanne). 2021 Aug 27;8:744625. doi: 10.3389/fmed.2021.744625. eCollection 2021.

VI.4 - The most significant citations corresponding to the research/artistic/other outputs
1

Levelling the Translational Gap for Animal to Human Efficacy Data.Ferreira GS, Veening-Griffioen DH, Boon WPC, Moors EHM, van Meer PJK.

Animals (Basel). 2020 Jul 15;10(7):1199. doi: 10.3390/ani10071199.

2

 Regulatory Standards in Orphan Medicinal Product Designation in the EU.

Tsigkos S, Mariz S, Sheean ME, Larsson K, Magrelli A, Stoyanova-Beninska V.

Front Med (Lausanne). 2021 Jun 25;8:698534. doi: 10.3389/fmed.2021.698534. eCollection 2021.

3

The translational value of animal models in orphan medicines designations for rare paediatric neurological diseases.Duarte DM, Beatriz da Silva Lima M, Sepodes B.

Regul Toxicol Pharmacol. 2020 Dec;118:104810. doi: 10.1016/j.yrtph.2020.104810. Epub 2020 Oct 26.

4

Preventive effects of nitrate-rich beetroot juice supplementation on monocrotaline-induced pulmonary hypertension in rats.Tawa M, Nagata R, Sumi Y, Nakagawa K, Sawano T, Ohkita M, Matsumura Y.

PLoS One. 2021 Apr 8;16(4):e0249816. doi: 10.1371/journal.pone.0249816. eCollection 2021.

5

Nitric Oxide and Endothelial Dysfunction.Cyr AR, Huckaby LV, Shiva SS, Zuckerbraun BS.

Crit Care Clin. 2020 Apr;36(2):307-321. doi: 10.1016/j.ccc.2019.12.009.

VI.5 - Participation in conducting (leading) the most important research projects or art projects over the last six years

VII. - Overview of organizational experience related to higher education and research/artistic/other activities

VII.a - Activity, position VII.b - Name of the institution, board VII.c - Duration
Member of the Committee for Orphan Medicinal Products European Medicines Agency 2016-

VIII. - Overview of international mobilities and visits oriented on education and research/artistic/other activities in the given field of study

IX. - Other relevant facts

Date of last update
2024-03-28